ethyl 3-(1-methyl-1H-pyrazol-3-yl)-3-oxopropanoate | 958132-55-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 3-(1-methyl-1H-pyrazol-3-yl)-3-oxopropanoate
• 英文别名: ethyl 3-(1-methylpyrazol-3-yl)-3-oxopropanoate
• CAS: 958132-55-3
• 化学式: C₉H₁₂N₂O₃
• mdl: MFCD04042422
• 分子量: 196.206
• InChiKey: ASHMSFPCQOVCJT-UHFFFAOYSA-N

物化性质

• 沸点：
  298.2±15.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(1-methyl-1H-pyrazol-3-yl)-3-oxopropanoate 在 sodium hydride 、 三乙胺 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents

  摘要：

  NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.

  DOI：

  10.1021/ml300134b
• 作为产物：
  描述：

  丙二酸单乙酯 、 正丁基锂 、 、 1-甲基-1H-吡唑-3-甲酰氯 、 乙酸乙酯 、 在 氮气 、 乙酸乙酯 、 碳酸氢钠 、 Brine 、 NH4OAc 、 乙腈 作用下， 以 四氢呋喃 为溶剂， 反应 4.75h， 以to get the title compound as a semi-solid (100 mg)的产率得到ethyl 3-(1-methyl-1H-pyrazol-3-yl)-3-oxopropanoate
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF

  摘要：

  本文描述了化学式(I)的化合物及其药学上可接受的盐。还描述了制备它们的过程，包含它们的制药组合物，以及它们作为药物治疗细菌感染的用途。

  公开号：

  US20100137313A1

文献信息

• [EN] KDM5 INHIBITORS<br/>[FR] INHIBITEURS DE KDM5
  申请人：MERCK SHARP & DOHME

  公开号：WO2018071282A1

  公开（公告）日：2018-04-19

  The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib): (I) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.

  本发明提供了一种化合物的化学式(I)（表示为互变异构体Ia和Ib）：(I)或其药学上可接受的盐，它们是KDM5抑制剂。
• KDM5 INHIBITORS
  申请人：MANSOOR Umar Faruk

  公开号：US20200048259A1

  公开（公告）日：2020-02-13

  The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib): (I) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
• [EN] HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ASTRAZENECA AB

  公开号：WO2010038081A2

  公开（公告）日：2010-04-08

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
• Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents
  作者：Pravin S. Shirude、Beena Paul、Nilanjana Roy Choudhury、Chaitanya Kedari、Balachandra Bandodkar、Bheemarao G. Ugarkar

  DOI：10.1021/ml300134b

  日期：2012.9.13

  NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.
• HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Boriack-Sjodin Ann

  公开号：US20100137313A1

  公开（公告）日：2010-06-03

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了化学式(I)的化合物及其药学上可接受的盐。还描述了制备它们的过程，包含它们的制药组合物，以及它们作为药物治疗细菌感染的用途。